Fusafungine ( INN), also known as fusafungin, is an active agent used in antibiotics for treatment of nasal and throat infection. It also possesses anti-inflammatory properties. Fusafungine is a mixture of enniatin cyclohexadepsipeptides made up of alternating D-α-hydroxyvaleric acid and L- N-methylamino acid residues, produced by the [2 ] ascomycete , and marketed by Fusarium lateritium Servier under the trade names Locabiotal, Bioparox, and Locabiosol.
According to a pooled analysis study done in the UK for the efficacy of fusafungine in
rhinopharingitis, it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo. [3 ]
References [ edit ]
^ Fusafungine at MeSH
^ Daniel Levy, Aline Bluzat, Michel Seigneuret and Jean-Louis Rigaud (1995). "Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins". Biochemical Pharmacology 50 (12 22): 2105–2107. doi: 10.1016/0006-2952(95)02045-4. PMID 8849339.
^ Lund, V. J.; Grouin, J. M.; Eccles, R; Bouter, C; Chabolle, F (2004). "Efficacy of fusafungine in acute rhinopharyngitis: A pooled analysis". Rhinology 42 (4): 207–12. PMID 15626253.